MedTrace Logo

Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)

NCT01455428 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

To prove pregabalin is effective in relieving pain compared with placebo in subjects with postherpetic neuralgia (PHN).

Conditions

  • Postherpetic Neuralgia ( PHN )

Interventions

DRUG

Lyrica (pregabalin)

Capsule, 300 mg/d, BID, 8 weeks treatment

DRUG

Placebo

Capsule, 300 mg/d, BID, 8 weeks treatment

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455428 on ClinicalTrials.gov